Table 2.
CD4 count and viral load results of client B (CB)
| Dates | CD4 count (cells/mm3) | Dates | Viral load (copies/ml) |
|---|---|---|---|
| 16/05/2015 | 339 | 24/03/2017 | 3,090 switched to the second line |
| 02/04/2016 | 244 | 05/07/2018 | 580 |
| 24/03/2017 | 203 | 07/02/2019 | 655 |
| 15/03/2018 | 453 | 07/02/2020 | 6,790 |
| 05/07/2018 | 576 | 20/07/2020 | 2,523 |
| 09/02/2021 | 4,162 transitioned to TLD | ||
| 08/05/2021 | <20 | ||
| 18/07/2022 | <20 |
The CD4 count of CB dropped from baseline, and there was also increased viral load about two years after commencement of ART, but it dropped when she was switched to second-line ART; TLD: Tenofovir Lamivudine, Dolutegravir antiretroviral therapy combination